Impact of anatomic site on antigen-presenting cells in cancer de réir Zagorulya, Maria, Duong, Ellen, Spranger, Stefani

Faigh an téacs iomlán

Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer de réir Neo, Shi Yong, Xu, Shengli, Chong, Joni, Lam, Kong-Peng, Wu, Jing

Faigh an téacs iomlán

Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 de réir Spranger, Stefani

Faigh an téacs iomlán

A2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models de réir Tay, Apple Hui Min, Prieto-Díaz, Rubén, Neo, Shiyong, Tong, Le, Chen, Xinsong, Carannante, Valentina, Önfelt, Björn, Hartman, Johan, Haglund, Felix, Majellaro, Maria, Azuaje, Jhonny, Garcia-Mera, Xerardo, Brea, Jose M., Loza, Maria I., Jespers, Willem, Gutierrez-de-Teran, Hugo, Sotelo, Eddy, Lundqvist, Andreas

Faigh an téacs iomlán

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer de réir Ricciuti, Biagio, Kravets, Sasha, Dahlberg, Suzanne E., Umeton, Renato, Albayrak, Adem, Subegdjo, Safiya J., Johnson, Bruce E., Nishino, Mizuki, Sholl, Lynette M., Awad, Mark M.

Faigh an téacs iomlán

Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma de réir Bao, Riyue, Spranger, Stefani, Hernandez, Kyle, Zha, Yuanyuan, Pytel, Peter, Luke, Jason J, Gajewski, Thomas F, Volchenboum, Samuel L, Cohn, Susan L, Desai, Ami V

Faigh an téacs iomlán

Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins de réir Fessenden, Tim B, Stopfer, Lauren E, Chatterjee, Fiona, Zulueta, Julian, Mesfin, Josh, Cordero Dumit, Therese, Reijers, Irene, Hoefsmit, Esmee P, Blank, Christian, White, Forest, Spranger, Stefani

Faigh an téacs iomlán

Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy) de réir Spranger-Zimmermann, Stefani

Faigh an téacs iomlán

A team effort: natural killer cells on the first leg of the tumor immunity relay race de réir Fessenden, Timothy B, Duong, Ellen, Spranger-Zimmermann, Stefani

Faigh an téacs iomlán
Faigh an téacs iomlán

Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma de réir Trujillo, Jonathan A, Luke, Jason J, Zha, Yuanyuan, Segal, Jeremy P, Ritterhouse, Lauren L, Spranger-Zimmermann, Stefani, Matijevich, Karen, Gajewski, Thomas F

Faigh an téacs iomlán

PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment de réir Collins, Natalie B, Al Abosy, Rose, Miller, Brian C, Bi, Kevin, Zhao, Qihong, Quigley, Michael, Ishizuka, Jeffrey J, Yates, Kathleen B, Pope, Hans W, Manguso, Robert T, Shrestha, Yashaswi, Wadsworth, Marc, Hughes, Travis, Shalek, Alex K, Boehm, Jesse S, Hahn, William C, Doench, John G, Haining, W Nicholas

Faigh an téacs iomlán

Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition de réir Naik, Girish, Waikar, Sushrut S., Johnson, Alistair Edward William, Buchbinder, Elizabeth I., Haq, Rizwan, Hodi, F. Stephen, Schoenfeld, Jonathan D., Ott, Patrick A.

Faigh an téacs iomlán